Stories

This moving personal story about the challenges of living with a rare disease is written by Rocco Falchetto, a biochemist and director of analytical sciences and imaging at the Novartis Institutes for BioMedical Research (NIBR).

The word “biopsy” typically conjures images of large needles. Lab technicians—and scientists working to discover new medicines—need enough tissue from a patient to prepare and evaluate a sample.

Over the next 15 years chronic disease like cancer and heart disease will become major killers in Sub-Saharan Africa. A new report from the Economist Intelligence Unit explains why.

Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.

In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.

Novartis hopes to prevent, treat and block malaria and is conducting clinical trials to test some promising therapies. Learn more.

Read how a genetics postdoctoral researcher finds Huntington's mutation travels through neural circuits.

Ogimi in Okinawa, Japan has the highest percentage of centenarians in the world, making it a curiosity for those eager to learn more about the secrets of aging.

Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.